The SPECTAlung Scientific team comprehends members of the Gustave Roussy Institute, Cancer Campus, Grand Paris in France , members of ETOP in Switzerland as well as members of the EORTC in Belgium.
MD, Study Coordinator, Gustave Roussy, Cancer Campus, Grand Paris, France
Dr Benjamin Besse is a full time cancer specialist at ‘Gustave Roussy, Cancer Campus, Grand Paris’, France. He gained his medical oncology degree in 2005 from Paris University and holds a doctoral degree in translational research. Currently, Dr Besse is Head of the Thoracic Oncology Unit at ‘Gustave Roussy, Cancer Campus, Grand Paris’. His main research interests are application of molecular abnormalities to personalize treatment, phase I trials in thoracic tumors and thymic tumors. He coordinates the French network for thymic malignancies (www.rythmic.org). He is associate editor of European Respiratory Journal.
MD, Gustave Roussy, Cancer Campus, Grand Paris, France
MD, Gustave Roussy, Cancer Campus, Grand Paris, France
Rolf A. Stahel, M.D.
President ETOP Foundation Council Clinic of Oncology, University Hospital Zürich, Switzerland
Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research and targeted therapy.
Since 2008 he is president of the foundation council of the International Breast Cancer Study Group (IBCSG) and currently he is president of ESMO (2014/2015).
MD, PhD, PD-MER, ETOP Scientific Coordinator
University of Lausanne, Switzerland
Solange Peters, MD-PhD, PD-MER, is in charge of the thoracic malignancies program in the Department of Oncology of the University of Lausanne, and active in building a translational program in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan as well as the Ludwig Institute. She has been trained in medical oncology and molecular biology in Switzerland and Italy. Her main field of interest is new biomarker discovery and validation in preclinical and clinical settings, as well as immunotherapy. She is also heavily involved and interested in developing multimodality trials for locally advanced NSCLC.
MD, Phd, Medical University of Gdansk, Poland, ETOP
Dr Rafal Dziadziuszko completed his training in Radiotherapy (2001) and Medical Oncology (2004) at the Department of Oncology and Radiotherapy of the Medical University of Gdansk, Poland.
He subsequently completed a translational cancer research fellowship at the University of Colorado Cancer Center. Between 2005 and 2007 he worked on predictive assays for EGFR targeted therapies in lung cancer, including immunohistochemistry, gene copy number, and activating mutations. He then returned to his home institution to serve as a deputy chair of the department.
Dr Dziadziuszko’s main interests include lung cancer translational and clinical research methodology, and he is a co-author of several peer-reviewed articles and book chapters on this topic. He is a member of the European Organisation for Research and Treatment of Cancer – Lung Cancer and Radiotherapy Groups, European Society for Medical Oncology, American Society of Clinical Oncology, and American Association for Cancer Research. He has also participated in the organisation of several academic clinical research studies in Poland and Central Europe through the Polish Lung Cancer Group and serves as the Vice-Chairman of the Central and East European Oncology Group.
His current work includes the identification of novel targets for lung cancer trials and early lung cancer detection. He has been involved in IGF-1R, ALK, and MET translational and clinical research.
Anita Hiltbrunner graduated as Professional Bachelor in Business Administration at HFW Berne. She has been working in cancer research administration for almost 25 years and gained profound work experience during that time. She acts as Director of both the International Breast Cancer Study Group IBCSG and ETOP. Anita Hiltbrunner is responsible for the financial management of the group, fosters the achievement of strategic and operational objectives of the Foundation and executes directions and instructions for the operation of the business established by the Foundation Council.
MB BAO BCh PhD FRCPath, ETOP Molecular Pathologist
Dr. Stephen Finn MB BAO BCh PhD FRCPath is a Consultant Molecular Pathologist at St. James’s Hospital and Associate Professor at the University of Dublin, Trinity College. He co-directs the Cancer Molecular Diagnostic Laboratory (CMD) at St. James’s. CMD is the only fully accredited molecular diagnostic laboratory for cancer in Ireland. Dr. Finn is a former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn’s research interests are primarily focused on lung cancer and prostate cancer. He is a member of ETOP and a founding member of the Transdisciplinary Prostate Cancer Partnership. Dr. Finn is a current recipient of the Prostate Cancer Foundation Young Investigator Award.
MD, EORTC Clinical Research Physician
Dr Jessica Menis is a medical oncologist with main interest in thoracic tumors. She gained her medical oncology degree in 2012 at Udine University (Italy) and attended for a fellowship on thoracic tumors the Thoracic Unit at AOU San Luigi Gonzaga in Orbassano (Italy). Currently, Dr Menis is Clinical Research Physician for the EORTC Lung and Head and Neck Cancer Groups at the EORTC Headquarters in Brussels (Belgium). Her main research interest is the development of phase I, II and III trials in lung cancer, malignant pleural mesothelioma and thymic tumors.
Molecular Biologist graduate from the “Université libre de Bruxelles”, Aline Gheeraert is the responsible Project Manager for the SPECTA Program in general as well as for all SPECTA platforms. She joined the EORTC in 2013 as Data Manager working mainly on brain cancer trials. In 2015 she switched to the Clinical Operation Department as Project Manager working on several international clinical trials in the Soft Tissue and Bone Sarcoma Group.
Translational Research Officer
Emilie Varin received her PhD in Biomolecules, Pharmacolgy, Therapeutics from the University of Caen Basse-Normandie (France) in 2010. After a first experience in the pharma industry, she joined the EORTC in 2012 as clinical project manager for the Gynecological Cancer Group. Since April 2013, she works in the Translational Research Unit which aims to provide support to data center teams for implementing translational research programs in EORTC clinical trials. She is particularly involved in the SPECTAlung and SPECTAmel(anoma) platforms.